Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis

Cytokine

Volumn 83, Issue , 2016, Pages 189-192

  Xiao, Yong Tao ^a,b,c   Yan, Wei Hui ^a,c   Cao, Yi ^a   Yan, Jun Kai ^b,c   Cai, Wei ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute for Pediatric Research   (China)

^c Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition   (China)

Author keywords

Claudin 2; Dextran sulfate sodium; IL 6; MLCK; TNF

Indexed keywords

CLAUDIN 2; DRINKING WATER; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MYOSIN LIGHT CHAIN KINASE; TUMOR NECROSIS FACTOR ALPHA; DEXTRAN SULFATE; INTERLEUKIN-6, MOUSE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PERMEABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; COLITIS; DEXTRAN SULFATE; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MICE; PERMEABILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964809967     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.04.012     Document Type: Article

References (18)

1. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
2. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. The American journal of gastroenterology. 2002, 97:2000-2004.
3. Su L., Nalle S.C., Shen L., Turner E.S., Singh G., Breskin L.A., et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013, 145:407-415.
4. El Mourabet M., El-Hachem S., Harrison J.R., Binion D.G. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr. Drug Targets 2010, 11:234-241.
5. Seegert D., Rosenstiel P., Pfahler H., Pfefferkorn P., Nikolaus S., Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001, 48:326-332.
6. Al-Sadi R., Ye D., Boivin M., Guo S., Hashimi M., Ereifej L., et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS One 2014, 9:e85345.
7. Suzuki T., Yoshinaga N., Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J. Biol. Chem. 2011, 286:31263-31271.
8. Ito H. Treatment of Crohn's disease with anti-IL-6 receptor antibody. J. Gastroenterol. 2005, 40(Suppl. 16):32-34.
9. Qiu W., Wu B., Wang X., Buchanan M.E., Regueiro M.D., Hartman D.J., et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J. Clin. Invest. 2011, 121:1722-1732.
10. Obermeier F., Kojouharoff G., Hans W., Scholmerich J., Gross V., Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 1999, 116:238-245.
11. Xiao Y., Wang J., Yan W., Zhou Y., Chen Y., Zhou K., et al. Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling. J. Hepatol. 2015, 62:889-896.
12. Furuta G.T., Turner J.R., Taylor C.T., Hershberg R.M., Comerford K., Narravula S., et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 2001, 193:1027-1034.
13. Yang Y., Wang W.S., Qiu Y., Sun L.H., Yang H. Role of cyclic adenosine monophosphate(cAMP) in the regulation of intestinal epithelial barrier function under hypoxia. J. Gastrointest. Surg. 2013, 16:479-483.
14. Watari A., Hasegawa M., Yagi K., Kondoh M. Checkpoint kinase 1 activation enhances intestinal epithelial barrier function via regulation of claudin-5 expression. PLoS One 2016, 11:e0145631.
15. Lee A.C., Katz J., Blencowe H., Cousens S., Kozuki N., Vogel J.P., et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Global Health 2013, 1:e26-e36.
16. Zhu D., Sun Y., Huo G.C., Yang L., Liu F., Li A., et al. Complete genome sequence of Bifidobacterium animalis subsp. lactis KLDS 2.0603, a probiotic strain with digestive tract resistance and adhesion to the intestinal epithelial cells. J. Biotechnol. 2016, 220:49-50.
17. Huang H., Liu J.Q., Yu Y., Mo L.H., Ge R.T., Zhang H.P., et al. Regulation of TWIK-related potassium channel-1 (Trek1) restitutes intestinal epithelial barrier function. Cell. Mol. Immunol. 2016, 13:110-118.
18. Ashraf R., Shah N.P. Immune system stimulation by probiotic microorganisms. Crit. Rev. Food Sci. Nutr. 2014, 54:938-956.